| |
Univariate
| |
Multivariate
| |
|---|
| |
HR (CI)
|
p-value
|
HR (CI)
|
p-value
|
|---|
|
Local control
|
|
Prior CTxa
|
2.19 (1.23–3.91)
|
0.008
|
2.19 (1.18–4.06)
|
0.13
|
|
Histology (CRC)
|
1.99 (1.31–3.04)
|
0.001
|
1.71 (1.04–2.80)
|
0.03
|
|
Histology (BCa)
|
0.53 (0.25–1.13)
|
0.10
|
0.45 (0.19–1.02)
|
0.06
|
|
Histology (NSCLC)
|
0.86 (0.26–2.85)
|
0.81
|
0.67 (0.19–2.35)
|
0.54
|
|
GTV Volumec
|
1.004 (1.002–1.005)
|
< 0.001
|
–
| |
|
PTV Volumec
|
1.002 (1.001–1.003)
|
< 0.001
|
1.001 (1.00–1.002)
|
0.003
|
|
BED Isocenterc
|
0.993 (0.989–0.997)
|
< 0.001
|
0.99 (0.98–1.00)
|
0.002
|
|
BED prescriptionc
|
0.72 (0.51–1.01)
|
0.003
|
1.00 (0.99–1.01)
|
0.970
|
|
Advanced Motion managementa
|
0.46 (0.29–0.72)
|
< 0.001
|
0.57 (0.33–0.96)
|
0.04
|
|
Before 2003a
|
1.50 (1.04–2.16)
|
0.031
|
1.02 (0.61–1.70)
|
0.932
|
|
Overall survival
|
|
KIc
|
0.69 (0.51–0.94)
|
0.02
|
0.74 (0.53–0.98)
|
0.06
|
|
Gender
|
0.80 (0.63–1.01)
|
0.06
|
0.76 (0.54–1.06)
|
0.10
|
|
Histology (CRC)
|
0.61 (0.46–0.79)
|
< 0.001
|
0.64 (0.45–0.92)
|
0.01
|
|
Histology (BCa)
|
0.52 (0.36–0.76)
|
< 0.001
|
0.60 (0.36–0.99)
|
0.05
|
|
Histology (NSCLC)
|
1.42 (0.87–2.33)
|
0.16
|
1.14 (0.64–2.07)
|
0.65
|
|
Prior CTxa
|
0.91 (0.65–1.27)
|
0.58
|
1.17 (0.76–1.80)
|
0.47
|
|
Extrahepatic statusb
|
0.81 (0.60–1.1)
|
0.18
|
0.83 (0.49–1.43)
|
0.52
|
|
Solitarya
|
0.73 (0.57–0.92)
|
0.007
|
1.12 (0.61–2.03)
|
0.72
|
|
# of liver metastases (1 vs. 2–4)
|
0.94 (0.72–1.23)
|
0.65
|
0.80 (0.52–1.23)
|
0.32
|
|
GTV Volumec
|
1.003 (1.002–1.004)
|
< 0.001
|
–
| |
|
PTV Volumec
|
1.002 (1.001–1.002)
|
< 0.001
|
1.002 (1.001–1.003)
|
< 0.001
|
|
Local recurrence after SBRTa
|
0.88 (0.68–1.51)
|
0.36
|
0.82 (0.56–1.19)
|
0.29
|
|
BED isocenterc
|
0.997 (0.994–1.00)
|
0.06
|
1.00 (0.99–1.004)
|
0.97
|
- CTx chemotherapy, BCa breast cancer, BED biologically effective dose, GTV gross tumor volume, PTV planning target volume, PS performance status, HR hazard ratio, CI 95% confidence interval), CRC corolrectal caner, NSCLC non-small cell lung cancer
- abinary coded variables with yes vs. no; bcomplete remission/stable disease vs progressive disease; cvolume and minimum biologically effective dose as continuous variables
